KRAS and colorectal carcinoma: Even though consensus molecular subtype (CMS) 3 is considered the metabolic CRC subtype with an upregulation of several metabolic pathways (not only fatty-acid metabolism but also glucose, fructose, nitrogen,... metabolism) and activating KRAS mutations5, we have already demonstrated that SARIFA-positive CRCs show an enrichment for CMS1/4 (immune/mesenchymal) and not for CMS311, indicating that SARIFA-positivity is not only associated with changes in fatty-acid metabolism11,12 but also dysregulated immunity14,16 and stromal changes11.